Paul Friedman, M.D. was appointed to the Board of Directors in July 2016. He currently serves as Chairman and Chief Executive Office of Madrigal Pharmaceuticals. Dr. Friedman previously served as the Chief Executive Officer and a Director of Incyte Corporation from 2001 until his retirement in 2014. From 1994 to 1998, he served as President of Research & Development for the DuPont-Merck Pharmaceutical Company; and from 1998 to 2001 as President of DuPont Pharmaceuticals Research Laboratories, a wholly-owned subsidiary of the DuPont Company. From 1991 to 1994, he served as Senior Vice President at Merck Research Laboratories. Prior to his tenures at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. He is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. Dr. Friedman currently serves on the board of directors of Madrigal Pharmaceuticals, Inc. He has previously served on the boards of directors of Incyte Corporation, Alexion Pharmaceuticals, Inc., Cerulean Pharma Inc. and Verastem, Inc. Dr. Friedman received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School.
A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.